4 completed, 2 recruiting. 1 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Sodium-Glucose Transporter 2: new trials by email Literature Review of Sodium-Glucose Transporter 2 trials Research Report on Sodium-Glucose Transporter 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2i, Pioglitazone, and Ketone Production in T2D Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d) - Type 2 Diabetes | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 64 | 2026-05-11 | 2026-07-17 |
| Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity Sodium-glucose transport-2 (SGLT-2) inhibitors, Standard medical treatment - Breast Cancer | Not applicable | Recruiting | University of Aberdeen | 70 | 2025-12-12 | 2026-04-30 |
| A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor - Diabetes Mellitus, Type 2 | Completed | Boehringer Ingelheim | 327624 | 2019-04-15 | 2024-09-23 | |
| Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors - Type2 Diabetes, Myocardial Infarction | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 419734 | 2018-10-01 | 2024-09-19 | |
| Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Other treatment combinations - Diabetes Mellitus, Type 2, Urosepsis | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1249636 | 2018-10-01 | 2024-09-19 | |
| A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey INSULIN GLARGINE (U300), metformin, sulfonylurea - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 112 | 2016-11-30 | 2019-01-14 |
Diabetes Mellitus, Type 2 (5) · Breast Neoplasms (1) · Diabetic Ketoacidosis (1) · Heart Failure (1) · Ischemic Stroke (1) · Myocardial Infarction (1)
Canadian Network for Observational Drug Effect Studies, CNODES (2) · Boehringer Ingelheim (1) · Sanofi (1) · The University of Texas Health Science Center at San Antonio (1) · University of Aberdeen (1)
Canada (2) · United Kingdom (2) · Denmark (1) · Finland (1) · Germany (1) · Israel (1) · Japan (1) · Norway (1) · South Korea (1) · Spain (1) · Sweden (1) · Taiwan (1) · Turkey (Türkiye) (1) · United States (1)
Pierre Ernst, MD, MSc, FRCPC (2) · Dana Dawson, MPhil (1) · Kimberly G Brodovicz, (203) 448-1937 (1) · Ralph DeFronzo, MD (1)
PMID 32383792, PMID 32716707, PMID 32759360, PMID 32967856, PMID 34332563, PMID 36097728, PMID 36175881
R01DK024092 (1)